We found no clinical ly meaningful blood pressure-lowering differences between different drugs within the loop diuretic class .
BACKGROUND Antihypertensive drugs from the thiazide diuretic drug class have been shown to reduce mortality and cardiovascular morbidity .
Loop diuretics are indicated and used to treat hypertension , but a systematic review of their blood pressure-lowering efficacy or effectiveness in terms of reducing cardiovascular mortality or morbidity from r and omized controlled trial ( RCT ) evidence has not been conducted .
OBJECTIVES To determine the dose-related decrease in systolic or diastolic blood pressure , or both , as well as adverse events leading to participant withdrawal and adverse biochemical effects ( serum potassium , uric acid , creatinine , glucose and lipids profile ) due to loop diuretics versus placebo control in the treatment of people with primary hypertension .
Involvement of Kallikrein in the Antihypertensive Response to Furosemide in Essential Hypertension
Summary : Twelve white men with essential hypertension were treated for 1 month in r and omized order with either placebo or low-dose furosemide ( 40 mg/day ) and compared to 22 race , age- , and diet-matched normal controls .  Furosemide therapy significantly reduced mean arterial pressure ( 108.6 ± 2.4 vs. 101.0 ± 2.7 mm Hg . p < 0.02 ) in association with a significant increase in 24 hr urinary kallikrein activity ( 7.9 ± 1.8 vs. 13.4 ± 2.8 esterase units/24 hr . p < 0.02 ) . Normal controls on no therapy excreted 19.4 ± 2.6 esterase units/24hr of urinary kallikrein activity , significantly greater than hypertensives on placebo ( p < 0.01 ) but not hypertensives on furosemide ( p < 0.01 ) . The decrease in mean arterial pressure and the increase in urinary kallikrein activity induced by furosemide were not associated with a demonstrable change in renal hemodynamics . plasma renin activity , or plasma aldosterone concentration , but they were associated with a significant increase in intravascular volume ( 5.876 ± 339 vs. 6.808 ± 346 ml . p < 0.01 ) . A significant ( p < 0.05 ) inverse correlation between mean arterial pressure and urinary kallikrein activity suggests a possible role for the kallikrein-kinin system in the antihypertensive mechanism of furosemide
We found no clinical ly meaningful blood pressure-lowering differences between different drugs within the loop diuretic class .
BACKGROUND Antihypertensive drugs from the thiazide diuretic drug class have been shown to reduce mortality and cardiovascular morbidity .
Loop diuretics are indicated and used to treat hypertension , but a systematic review of their blood pressure-lowering efficacy or effectiveness in terms of reducing cardiovascular mortality or morbidity from r and omized controlled trial ( RCT ) evidence has not been conducted .
OBJECTIVES To determine the dose-related decrease in systolic or diastolic blood pressure , or both , as well as adverse events leading to participant withdrawal and adverse biochemical effects ( serum potassium , uric acid , creatinine , glucose and lipids profile ) due to loop diuretics versus placebo control in the treatment of people with primary hypertension .